Publications

Found 403 results
2017
Kasturi SPai, Kozlowski PA, Nakaya HI, Bürger MC, Russo P, Pham M, Kovalenkov Y, Silveira ELV, Havenar-Daughton C, Burton SL et al..  2017.  Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.. J Virol. 91(4)
Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, Murrell B, Pfeifer N, Nogueira L, Oliveira TY et al..  2017.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.. Nat Med. 23(2):185-191.
Lee J H, Andrabi R, Su C-Y, Yasmeen A, Julien J-P, Kong L, Wu NC, McBride R, Sok D, Pauthner M et al..  2017.  A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.. Immunity. 46(4):690-702.
Richard J, Prévost J, von Bredow B, Ding S, Brassard N, Medjahed H, Coutu M, Melillo B, Bibollet-Ruche F, Hahn BH et al..  2017.  BST-2 Expression Modulates Small CD4 Mimetic Sensitization of HIV-1-infected cells to ADCC.. J Virol. 91(11):pii:e00219-17.
Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb KE, Wiesch JSchulze Zu, Cubas R, Porichis F, Shalek AK et al..  2017.  Circulating CXCR5(+)CXCR3(+)PD-1(lo) Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth.. JCI Insight. 2(2):e89574.
Freund NT, Wang H, Scharf L, Nogueira L, Horwitz JA, Bar-On Y, Golijanin J, Sievers SA, Sok D, Cai H et al..  2017.  Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.. Sci Transl Med. 9(373):pii:eaa12144.
Bale S, Goebrecht G, Stano A, Wilson R, Ota T, Tran K, Ingale J, Zwick MB, Wyatt RT.  2017.  Covalent Linkage of HIV-1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses.. J Virol. 91(16):pii:e00443-17.
Antunes Rda Silva, Paul S, Sidney J, Weiskopf D, Dan JM, Phillips E, Mallal S, Crotty S, Sette A, Arlehamn CSLindesta.  2017.  Definition of Human Epitopes Recognized in Tetanus Toxoid and Development of an Assay Strategy to Detect Ex Vivo Tetanus CD4+ T Cell Responses.. PLoS One. 12(1):e0169086.
Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens A-J, Ozorowski G et al..  2017.  Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.. J Exp Med. 214(9):2573-2590.
Haynes BF, Burton DR.  2017.  Developing an HIV vaccine.. Science. 355(6330):1129-1130.
Morris CD, Azadnia P, de Val N, Vora N, Honda A, Giang E, Saye-Francisco K, Cheng Y, Lin X, Mann CJ et al..  2017.  Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.. MBio. 8(1):pii:e00036-17.
Nishimura Y, Gautam R, Chun T-W, Sadjadpour R, Foulds KE, Shingai M, Klein F, Gazumyan A, Golijanin J, Donaldson M et al..  2017.  Early antibody therapy can induce long-lasting immunity to SHIV.. Nature. 543(7646):559-563.
Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, Carnathan DG, Chandrashekar A, Cirelli KM, Cottrell CA et al..  2017.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.. Immunity. 46(6):1073-1088.e6.
Cirelli KM, Crotty S.  2017.  Germinal center enhancement by extended antigen availability.. Curr Opin Immunol. 47:64-69.
Struwe WB, Stuckmann A, Behrens A-J, Pagel K, Crispin M.  2017.  Global N-Glycan Site Occupancy of HIV-1 gp120 by Metabolic Engineering and High-Resolution Intact Mass Spectrometry.. ACS Chem Biol. 12(2):357-361.
Cao L, Diedrich JK, Kulp DW, Pauthner M, He L, Park S-KRobin, Sok D, Su CYao, Delahunty CM, Menis S et al..  2017.  Global site-specific N-glycosylation analysis of HIV envelope glycoprotein.. Nat Commun. 8:14954.
Andrabi R, Su C-Y, Liang C-H, Shivatare SS, Briney B, Voss JE, Nawazi SKhan, Wu C-Y, Wong C-H, Burton DR.  2017.  Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.. Immunity. 47(3):524-537.
Guenaga J, Garces F, de Val N, Stanfield RL, Dubrovskaya V, Higgins B, Carrette B, Ward AB, Wilson IA, Wyatt RT.  2017.  Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein.. Immunity. 46(5):792-803.e3.
Laher F, Ranasinghe S, Porichis F, Mewalal N, Pretorius K, Ismail N, Buus S, Stryhn A, Carrington M, Walker BD et al..  2017.  HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer(+) Gag-Specific CD4(+) T Cells in Chronic Clade C HIV-1 Infection.. J Virol. 91(7):e02477-16.
Ward AB, Wilson IA.  2017.  The HIV-1 envelope glycoprotein structure: nailing down a moving target.. Immunol Rev. 275(1):21-32.
McCoy LE, Burton DR.  2017.  Identification and specificity of broadly neutralizing antibodies against HIV.. Immunol Rev. 275(1):11-20.
Alsahafi N, Richard J, Prévost J, Coutu M, Brassard N, Parsons MS, Kaufmann DE, Brockman M, Finzi A.  2017.  Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity.. J Virol. 91(16):pii:e00109-17.
A de la Peña T, Julien J-P, de Taeye SW, Garces F, Guttman M, Ozorowski G, Pritchard LK, Behrens A-J, Go EP, Burger JA et al..  2017.  Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.. Cell Rep. 20(8):1805-1817.
Prévost J, Zoubchenok D, Richard J, Veillette M, Pacheco B, Coutu M, Brassard N, Parsons MS, Ruxrungtham K, Bunupuradah T et al..  2017.  Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses.. J Virol. 91(7):pii:e02452-16.
Irimia A, Serra AM, Sarkar A, Jacak R, Kalyuzhniy O, Sok D, Saye-Francisco KL, Schiffner T, Tingle R, Kubitz M et al..  2017.  Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design.. PLoS Pathog. 13(2):e1006212.

Pages